Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 17 2022 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022 (No. 3)
Commission File Number 001-37846
QUOIN PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Azrieli Center, Round Tower, 30th
Floor
132 Menachem Begin Blvd
Tel Aviv, 6701101
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ________
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ________
EXPLANATORY NOTE
Business Updates
Quoin Pharmaceuticals Ltd. (the “Company”)
is an emerging specialty pharmaceutical company dedicated to developing products that help treat rare and orphan diseases for which there
are currently no approved treatments. The Company’s initial focus is on the development of products, using its proprietary owned
and in-licensed technology, that could help address rare skin diseases for which there are currently no approved treatments or cures.
Its first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with
the proprietary Invisicare® technology, to treat Netherton Syndrome. In addition, the Company intends to pursue the clinical development
of QRX003 in other rare dermatological diseases, including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. The Company’s
three other pipeline products in development are also targeting rare skin diseases, including Epidermolysis Bullosa, Netherton Syndrome
and Scleroderma.
The Company announces material financial information
to its investors using its investor relations website (https://investors.quoinpharma.com/), SEC filings and press releases. The Company
uses these channels as well as social media to communicate with the public about the Company, its products and other issues. It is possible
that the information the Company posts on social media could be deemed to be material information. Therefore, the Company encourages investors,
the media and others interested in the Company to review the information the Company posts on the U.S. social media channels listed below.
This list may be updated from time to time on the Company’s investor relations website.
The Company’s LinkedIn Page (https://www.linkedin.com/company/quoin-pharmaceuticals/)
The Company’s Twitter Account (@Quoinpharma)
License and Distribution Agreement
On June 14, 2022, Quoin Pharmaceuticals, Inc.,
a wholly-owned subsidiary of the Company, entered into a License and Distribution Agreement (the “License Agreement”) with
WinHealth Investment (HK) Limited (“WinHealth”). Under the terms of the License Agreement, WinHealth has the exclusive rights
to commercialize, upon the receipt of applicable regulatory approvals, pharmaceutical products QRX003 and QRX004 (in finished dosage form
for human use) in Greater China, including Hong Kong, Macau and Taiwan.
The foregoing description of the License Agreement
does not purport to be complete and is qualified in its entirety by reference to the complete text of such License Agreement, attached
hereto as Exhibit 10.1 and incorporated by reference herein.
The information in this Form 6-K, including
the exhibits hereto, shall be incorporated by reference into the Company’s registration statements on Form S-8 (Registration Nos.
333-214817, 333-220015, 333-225003 and 333-232230) and on Form F-3 (Registration Nos. 333-219614, 333-229083 and 333-265596).
Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: June 16, 2022 |
QUOIN PHARMACEUTICALS LTD. |
|
|
|
|
|
By: |
/s/ Gordon Dunn |
|
Name: |
Gordon Dunn |
|
Title: |
Chief Financial Officer |
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2023 to Aug 2024